title: Frequent loss of p19INK4D expression in hepatocellular carcinoma: relationship             to tumor differentiation and patient survival.
abstract: p19INK4D belongs to the family of cyclin-dependent kinase inhibitors (CdkIs)             that target the cyclin-dependent kinases and inhibit their catalytic activity.             The role of p19INK4D in cell cycle progression in hepatocellular carcinoma (HCC)             is poorly characterized. The aim of this study was to examine the expression of             p19INK4D in various liver diseases including HCC and to assess its clinical significance             in HCC. We examined the expression of p19INK4D by immunohistochemistry in 81 cases             of various liver diseases, including 51 HCCs. We analyzed the relationship among             p19INK4D expression in HCC in combination with histopathological stage, differentiation,             several histopathological factors of possible prognostic value and patient survival.             Immunohistochemical analysis revealed the frequent loss of p19INK4D expression             consistent with the differentiation of HCC. The loss of p19INK4D expression was             shown to be associated with a poor prognosis by analyzing clinicopathological             features. In conclusion, we found that loss of p19INK4D protein was frequent in             HCC, especially in poorly differentiated HCC, suggesting that p19INK4D may play             a role in the differentiation of HCC. Furthermore, expression of p19INK4D may             be an effective predictor of clinical behavior in HCC, and therefore, a new prognostic             marker for HCC.
authors: Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA. am2925@columbia.edu
authors: Asahiro
authors: A
authors: Morishita
authors: Jian
authors: J
authors: Gong
authors: Akihiro
authors: A
authors: Deguchi
authors: Joji
authors: J
authors: Tani
authors: Hisaaki
authors: H
authors: Miyoshi
authors: Hirohito
authors: H
authors: Yoshida
authors: Takashi
authors: T
authors: Himoto
authors: Hirohito
authors: H
authors: Yoneyama
authors: Hirohito
authors: H
authors: Mori
authors: Kiyohito
authors: K
authors: Kato
authors: Kazutaka
authors: K
authors: Kurokohchi
authors: Kazushi
authors: K
authors: Deguchi
authors: Kunihiko
authors: K
authors: Izuishi
authors: Yasushi
authors: Y
authors: Suzuki
authors: Yoshio
authors: Y
authors: Kushida
authors: Reiji
authors: R
authors: Haba
authors: Hisaaki
authors: H
authors: Iwama
authors: Seishiro
authors: S
authors: Watanabe
authors: Jeanine
authors: J
authors: D'Armiento
authors: Tsutomu
authors: T
authors: Masaki
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000378:metabolism* / Q000473:pathology; D050764:Cyclin-Dependent Kinase Inhibitor p19 / Q000235:genetics / Q000378:metabolism*; D005260:Female; D015870:Gene Expression; D006521:Hepatitis, Chronic / Q000378:metabolism / Q000473:pathology; D006801:Humans; D008103:Liver Cirrhosis / Q000378:metabolism / Q000473:pathology; D008113:Liver Neoplasms / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D060787:Neoplasm Grading; D011379:Prognosis; D016016:Proportional Hazards Models
chemical_list: D050764:Cyclin-Dependent Kinase Inhibitor p19